Eyenovia Inc

NASDAQ:EYENUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.

Contact Information

Headquarters

295 Madison Ave Ste 2400NEW YORK, NY, United States 10017

Phone

813-766-9539

Fax

302-636-5454

Executives

Chairman of the Board, Chief Executive Officer, Chief Medical Officer

Tsontcho Ianchulev

Chief Executive Officer, Director

Michael Rowe

Chief Financial Officer, Treasurer, Secretary

Andrew Jones

Chief Operating Officer

Bren Kern

Independent Director

Michael Geltzeiler